Nicholas Goldner
InvestorFounderVenture Partner at Alix Ventures · CEO/Founder at ResistanceBio
San Francisco Bay Area
Writes $200K – $300K checks · typically $250K
FoundedResistanceBio · YC
About
Nick Goldner is a founder and investor with a PhD in Molecular and Cellular Biology from Washington University in St. Louis, where he identified the molecular drug target of the antibiotic Daptomycin. He founded Viosera Therapeutics, an antibiotic company where he led IP strategy resulting in issued patents across the US, EU, China, and Japan, and later founded resistanceBio, an oncology services company. He now serves as a Venture Partner at Alix Ventures, focusing on early-stage life science and TechBio startups, and was previously a venture partner at Pioneer Fund covering biotech.
Contact· published on Nicholas's own website
Invests in
AI & Machine LearningBiotechHealthtech
CEO/Founder at ResistanceBioYC W19
Intro paths
Nicholas went through Y Combinator (Winter 2019) — any YC alum in your network can reach them through the YC community.
In turn, Nicholas can intro founders to ResistanceBio's investors below.
ResistanceBio's investors · 3
Co-founders at ResistanceBio
Experience
- Alix VenturesVenture Partnercurrent2025 — presentSan Francisco Bay Area
- Angel InvestorAngel Investorcurrent2019 — present
- Pioneer FundVenture Partnercurrent2019 — presentSan Francisco Bay Area
- resistanceBioChief Marketing Officer and SVP of Product2024Menlo Park, California, United States
- resistanceBioFounder2021 — 2024Menlo Park, California, United States
- resistanceBioChief Executive Officer2021 — 2023Menlo Park, California, United States
- Viosera TherapeuticsCEO and Co-founder2016 — 2021Greater St. Louis
Skills & more
+1 more
GeneticsLanguages English · German
From Nicholas's professional profile.
Colleagues at Alix Ventures
Frequently asked questions
- Who is Nicholas Goldner?
- Nick Goldner is a founder and investor with a PhD in Molecular and Cellular Biology from Washington University in St. Louis, where he identified the molecular drug target of the antibiotic Daptomycin. He founded Viosera Therapeutics, an antibiotic company where he led IP strategy resulting in issued patents across the US, EU, China, and Japan, and later founded resistanceBio, an oncology services company. He now serves as a Venture Partner at Alix Ventures, focusing on early-stage life science and TechBio startups, and was previously a venture partner at Pioneer Fund covering biotech.
- Where does Nicholas Goldner work?
- Nicholas Goldner is CEO/Founder of ResistanceBio and Venture Partner at Alix Ventures.
- What does Nicholas Goldner invest in?
- Nicholas Goldner invests in AI & Machine Learning, Biotech, Healthtech.
- What check size does Nicholas Goldner write?
- Nicholas Goldner typically writes checks of $200K – $300K.
- What companies did Nicholas Goldner found?
- Nicholas Goldner founded ResistanceBio.
- Where did Nicholas Goldner go to school?
- Nicholas Goldner studied at Y Combinator; Washington University School of Medicine in St. Louis (Doctor of Philosophy, Evolution and Molecular Biology); Washington University School of Medicine in St. Louis (Doctor of Philosophy).
Founder mafias
Y Combinator mafia8,773
Also came through, then founded or led a company.
+ 8,766 more
Y Combinator mafia4,716
Also came through, then founded or led a company.
+ 4,709 more
Washington University School of Medicine in St. Louis mafia6
Also came through, then founded or led a company.
Alix Ventures mafia3
Also came through, then founded or led a company.
Same school
Also attended Y Combinator2,000
+ 1,994 more
Also attended Washington University School of Medicine in St. Louis12
+ 6 more
